-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Immix Biopharma, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to Q3 2025.
- Immix Biopharma, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$7.59M, a 6.1% decline year-over-year.
- Immix Biopharma, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$23.6M, a 7.64% decline year-over-year.
- Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$21.6M, a 40.1% decline from 2023.
- Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$15.4M, a 87.4% decline from 2022.
- Immix Biopharma, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$8.23M, a 66.2% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)